Skip to content
Medical Health Aged Care

Envision Pharma Group Announces New AI Innovation Board and Appoints Chairwoman

Envision Pharma Group 3 mins read

The new board and leadership appointment aligns with the company's commitment to advancing the industry through innovation and the expansion of AI across its solutions

HORSHAM, UK / ACCESSWIRE / November 15, 2023 / Envision Pharma Group (Envision), a leading global technology-enabled strategic solutions partner for the life sciences industry, unveils its AI Innovation Board and announces the appointment of Dr. Loubna Bouarfa as AI thought leader and Chairwoman of the newly established board. This strategic move underscores Envision's global commitment to harnessing the power of AI to shape the future of the life sciences industry.

Previously serving as the CEO and founder of OKRA.ai, which was acquired by Envision in February 2023, Dr. Bouarfa revolutionized healthcare by creating AI systems that support life sciences companies to better enable the drive of personalized medicine across the globe. In this new role, she will apply her deep expertise to intertwine AI with all the services that Envision offers.

"Loubna's appointment and the establishment of the new AI Innovation Board marks a significant step toward aligning our innovation and technology efforts to drive our strategies for our internal team, business, and partners," shares Howard Miller, CEO of Envision Pharma Group. "We are confident this strategic move will propel Envision to new heights."

In her new role, Dr. Bouarfa will focus on advancing AI strategy and promoting its integration across all aspects of Envision. This appointment solidifies Envision's dedication to leveraging AI to deliver innovative, faster outcomes for the life sciences industry. In addition, Dr. Bouarfa will lead the AI Innovation Board to define and develop Envision's AI strategy across all technology platforms, solidify thought leadership as pioneers in AI, and pilot new innovative AI applications.

Having earned the Deloitte Fast 50 Women in Leadership Award and a place on Forbes' 50 Top Women in Tech list, Dr. Bouarfa expressed her commitment to the role, saying, "I am excited to take on this new challenge and continue driving AI innovation at Envision. We are dedicated to leading the industry in this space and delivering innovative solutions that will transform the future of life sciences. Our success will not only bring commercial benefit to clients but lead to improved patient outcomes across the globe."

###

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 19 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information

Colleen Carter
Associate Director, Communications, Office of CEO
[email protected]
1 (508) 505 8856

SOURCE: Envision Pharma Group

.


View source version on accesswire.com:
https://www.accesswire.com/803386/envision-pharma-group-announces-new-ai-innovation-board-and-appoints-chairwoman

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.